<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34905418</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myristicin regulates proliferation and apoptosis in oxidized low-density lipoprotein-stimulated human vascular smooth muscle cells and human umbilical vein endothelial cells by regulating the PI3K/Akt/NF-κB signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>56</StartPage>
          <EndPage>64</EndPage>
          <MedlinePgn>56-64</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2021.2010775</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Atherosclerosis (AS) is a chronic inflammatory disease. Human vascular smooth muscle cell (hVSMC) accumulation and human umbilical vein endothelial cell (HUVEC) dysfunction are associated with the pathogenesis of AS. This study explores whether myristicin plays a protective role in AS.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">hVSMCs and HUVECs were stimulated with 100 μg/mL oxidized low-density lipoprotein (ox-LDL) to establish a cellular model of AS. Cell viability, lactate dehydrogenase (LDH) release and cell apoptosis were evaluated using MTT, LDH and flow cytometry assays, respectively. Cell migration and inflammatory cytokine release were assessed using Transwell assay and ELISA.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Myristicin (5, 10, 25, and 50 μM) had no obvious effect on cell viability or the activity of LDH in hVSMCs, while 100 and 200 μM myristicin markedly suppressed hVSMCs viability and increased LDH release. Myristicin had no obvious effect on cell viability or the activity of LDH in HUVECs. Myristicin inhibited viability and increased apoptosis in ox-LDL-treated hVSMCs, but was associated with increased proliferation and inhibited apoptosis in HUVECs stimulated by ox-LDL. Additionally, myristicin markedly suppressed ox-LDL-induced hVSMCs migration and the release of inflammatory cytokines, including MCP-1, IL-6, VCAM-1 and ICAM-1, in HUVECs. Results also demonstrated that the promoting effects of ox-LDL on the PI3K/Akt and NF-κB signalling pathway in both hVSMCs and HUVECs were abolished by treatment with myristicin.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="CONCLUSIONS">Myristicin regulated proliferation and apoptosis by regulating the PI3K/Akt/NF-κB signalling pathway in ox-LDL-stimulated hVSMCs and HUVECs. Thus, myristicin may be used as a new potential drug for AS treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Ganzhou People's Hospital, Ganzhou, Jiangxi, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Huiying</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Ganzhou People's Hospital, Ganzhou, Jiangxi, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Luoying</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Ganzhou People's Hospital, Ganzhou, Jiangxi, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081248">Allylbenzene Derivatives</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004148">Dioxolanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C099252">oxidized low density lipoprotein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>04PD6CT78W</RegistryNumber>
          <NameOfSubstance UI="C005246">myristicin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000081248" MajorTopicYN="N">Allylbenzene Derivatives</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004148" MajorTopicYN="N">Dioxolanes</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Coronary heart disease</Keyword>
        <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
        <Keyword MajorTopicYN="N">migration</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>17</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34905418</ArticleId>
        <ArticleId IdType="pmc">PMC8676624</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2021.2010775</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Berenji AS, Eftedal I, Pedersen M, Jeppesen PB, Norregaard R, Matchkov VV.. 
2020. Endothelial dysfunction in small arteries and early signs of atherosclerosis in ApoE knockout rats. Sci Rep. 10(1):15296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7499202</ArticleId>
            <ArticleId IdType="pubmed">32943715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bian W, Jing X, Yang Z, Shi Z, Chen R, Xu A, Wang N, Jiang J, Yang C, Zhang D, et al. . 
2020. Downregulation of LncRNA NORAD promotes ox-LDL-induced vascular endothelial cell injury and atherosclerosis. Aging. 12(7):6385–6400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7185106</ArticleId>
            <ArticleId IdType="pubmed">32267831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao Z, Xia W, Zhang X, Yuan H, Guan D, Gao L.. 
2020. Hepatotoxicity of nutmeg: a pilot study based on metabolomics. Biomed Pharmacother. 131:110780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33152938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colaiori I, Izzo R, Barbato E, Franco D, Di Gioia G, Rapacciuolo A, Bartunek J, Mancusi C, Losi MA, Strisciuglio T, et al. . 
2019. Severity of coronary atherosclerosis and risk of diabetes mellitus. JCM. 8(7):1069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6678313</ArticleId>
            <ArticleId IdType="pubmed">31330868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fashanu OE, Oyenuga AO, Zhao D, Tibuakuu M, Mora S, Otvos JD, Stein JH, Michos ED.. 
2019. GlycA, a novel inflammatory marker and its association with peripheral arterial disease and carotid plaque: the multi-ethnic study of atherosclerosis. Angiology. 70(8):737–746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6663563</ArticleId>
            <ArticleId IdType="pubmed">31030528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feig JE, Vengrenyuk Y, Reiser V, Wu C, Statnikov A, Aliferis CF, Garabedian MJ, Fisher EA, Puig O.. 
2012. Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLOS One. 7(6):e39790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3384622</ArticleId>
            <ArticleId IdType="pubmed">22761902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu Y, Sun S, Sun H, Peng J, Ma X, Bao L, Ji R, Luo C, Gao C, Zhang X, et al. . 
2019. Scutellarin exerts protective effects against atherosclerosis in rats by regulating the Hippo-FOXO3A and PI3K/AKT signaling pathways. J Cell Physiol. 234(10):18131–18145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30891776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gistera A, Hansson GK.. 
2017. The immunology of atherosclerosis. Nat Rev Nephrol. 13(6):368–380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28392564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu SG, Li H, Kang PF, Chen TP, Li MN, Zhu J, Gao DS, Zhang H, Wang HJ.. 
2007. Effects of simvastatin on aortic vascular endothelial cell apoptosis and Bcl-2 protein expression in a rat model of atherosclerosis. Nan Fang Yi Ke Da Xue Xue Bao. 37:1456–1460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6779642</ArticleId>
            <ArticleId IdType="pubmed">29180324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu WN, Duan ZY, Wang Q, Zhou DH.. 
2019. The suppression of ox-LDL-induced inflammatory response and apoptosis of HUVEC by lncRNA XIAT knockdown via regulating miR-30c-5p/PTEN axis. Eur Rev Med Pharmacol Sci. 23(17):7628–7638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31539155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keller PF, Barthassat V, Scherrer-Burri F, Lagger G, Carballo S.. 
2008. Fighting heart attacks and atherosclerosis: a therapeutical challenge. Rev Med Suisse. 4(159):1345–1346. 1348-1349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18592727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li LX, Zhang XF, Bai X, Tong Q.. 
2013. SDF-1 promotes ox-LDL induced vascular smooth muscle cell proliferation. Cell Biol Int. 37(9):988–994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23658061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözoğlu L, Lewis EF.. 
2019. Atherosclerosis. Nat Rev Dis Primers. 5(1):56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31420554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Zhu Y, Wu Y, Liu Y, Teng Z, Hao Y.. 
2017. Association of carotid atherosclerosis and recurrent cerebral infarction in the Chinese population: a meta-analysis. NDT. 13:527–533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5325114</ArticleId>
            <ArticleId IdType="pubmed">28260898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livak KJ, Schmittgen TD.. 
2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2–ΔΔCq method. Methods. 25(4):402–408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11846609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu G, Chu Y, Tian P.. 
2021. Knockdown of H19 attenuates ox-LDL-induced vascular smooth muscle cell proliferation, migration and invasion by regulating miR-599/PAPPA axis. J Cardiovasc Pharmacol. 77(3):386–396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33235026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins C, Doran C, Silva IC, Miranda C, Rueff J, Rodrigues AS.. 
2014. Myristicin from nutmeg induces apoptosis via the mitochondrial pathway and down regulates genes of the DNA damage response pathways in human leukaemia K562 cells. Chem Biol Interact. 218:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24792648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morita T, Jinno K, Kawagishi H, Arimoto Y, Suganuma H, Inakuma T, Sugiyama K.. 
2003. Hepatoprotective effect of myristicin from nutmeg (Myristica fragrans) on lipopolysaccharide/d-galactosamine-induced liver injury. J Agric Food Chem. 51(6):1560–1565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12617584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pashapoor A, Mashhadyrafie S, Mortazavi P.. 
2020. Ameliorative effect of Myristica fragrans (nutmeg) extract on oxidative status and histology of pancreas in alloxan induced diabetic rats. Folia Morphol. 79(1):113–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31063201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simion V, Zhou H, Pierce JB, Yang D, Haemmig S, Tesmenitsky Y, Sukhova G, Stone PH, Libby P, Feinberg MW.. 
2020. LncRNA VINAS regulates atherosclerosis by modulating NF-kappaB and MAPK signaling. JCI Insight. 5(21):e140627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7710319</ArticleId>
            <ArticleId IdType="pubmed">33021969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soltani B, Bodaghabadi N, Mahpour G, Ghaemi N, Sadeghizadeh M.. 
2016. Nanoformulation of curcumin protects HUVEC endothelial cells against ionizing radiation and suppresses their adhesion to monocytes: potential in prevention of radiation-induced atherosclerosis. Biotechnol Lett. 38(12):2081–2088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27558390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao K, Hu Z, Zhang Y, Jiang D, Cheng H.. 
2019. LncRNA CASC11 improves atherosclerosis by downregulating IL-9 and regulating vascular smooth muscle cell apoptosis and proliferation. Biosci Biotechnol Biochem. 83(7):1284–1288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30915898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang G, Gao JH, He LH, Yu XH, Zhao ZW, Zou J, Wen FJ, Zhou L, Wan XJ, Tang CK.. 
2020. Fargesin alleviates atherosclerosis by promoting reverse cholesterol transport and reducing inflammatory response. Biochim Biophys Acta Mol Cell Biol Lipids. 1865(5):158633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31988050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Zheng X, Cheng J, Zhang K, Ma C.. 
2020. LncRNA TUG1 regulates proliferation and apoptosis by regulating miR-148b/IGF2 axis in ox-LDL-stimulated VSMC and HUVEC. Life Sci. 243:117287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31926240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Li T, Zha L.. 
2020. Foxc2 alleviates ox-LDL-induced lipid accumulation, inflammation, and apoptosis of macrophage via regulating the expression of Angptl2. Inflammation. 43(4):1397–1410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32170602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Song G, Yuan J, Qiao S, Xu S, Si Z, Yang Y, Xu X, Wang A.. 
2020. Circular RNA circ_0003204 inhibits proliferation, migration and tube formation of endothelial cell in atherosclerosis via miR-370-3p/TGFbetaR2/phosph-SMAD3 axis. J Biomed Sci. 27(1):11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6941276</ArticleId>
            <ArticleId IdType="pubmed">31900142</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
